![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The financed Proceeds will be used for the clinical development of the lead candidate, RNDP-001, an iPSC-derived, allogeneic dopamine progenitor cell therapy. Which is currently evaluated in the preclinical studies for the treatment of Parkinson’s disease.
Lead Product(s): RNDP-001
Therapeutic Area: Neurology Product Name: RNDP-001
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Alaska Permanent Fund Corporation
Deal Size: $82.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing February 29, 2024